Beta-arrestin biased agonism/antagonism at cardiovascular seven transmembrane-spanning receptors

Current Pharmaceutical Design

Volumn 18, Issue 2, 2012, Pages 192-198

  Lymperopoulos, Anastasios ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

adrenergic receptor; arrestin biased agonist or antagonist; arrestin dependent signalling; Angiotensin II type 1 receptor; Cardiovascular; Heptahelical receptor (7TMR)

Indexed keywords

ALDOSTERONE; ALPHA 2 ADRENERGIC RECEPTOR; ANGIOTENSIN 2 RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ARRESTIN; BRIMONIDINE; CANDESARTAN; FENOTEROL; G PROTEIN COUPLED RECEPTOR; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINIC RECEPTOR; SEVEN TRANSMEMBRANE SPANNING RECEPTOR; UNCLASSIFIED DRUG; VALSARTAN;

ALDOSTERONE BLOOD LEVEL; CARDIOVASCULAR SYSTEM; CONGESTIVE HEART FAILURE; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE OVEREXPRESSION; HEART INFARCTION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARRESTINS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; G-PROTEIN-COUPLED RECEPTOR KINASES; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; LIGANDS; PHOSPHORYLATION; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84856475827     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799040475     Document Type: Review

References (72)

1. Lander E S, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
2. Venter JC, Adams MD, Myers, et al. The sequence of the human genome. Science 2001; 291: 1304-51.
3. Flower DR. Modeling G-protein-coupled receptors for drug design. Biochem Biophys Acta 1999; 1422: 207-34.
4. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001; 53: 1-24.
5. Hata JA, Koch WJ. Phosphorylation of G protein-coupled receptors: GPCR kinases in heart disease. Mol Interv 2003; 3: 264-72.
6. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembranespanning receptors and heart function. Nature 2002; 415: 206-12.
7. Reiter E, Lefkowitz RJ. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Tr Endocrinol Metab 2006; 17: 159-265.
8. Gurevich VV, Gurevich EV. The structural basis of arrestinmediated regulation of G-protein-coupled receptors. Pharmacol Ther 2006; 110: 465-502.
9. Shukla AK, Violin JD, Whalen EJ, Gesty-Palmer D, Shenoy SK, Lefkowitz RJ. Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc Natl Acad Sci USA 2008; 105: 9988-93.
10. Gurevich VV, Pals-Rylaarsdam R, Benovic JL, Hosey MM, Onorato JJ. Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity. J Biol Chem 1997; 272: 28849-52.
11. Stoffel RH 3rd, Pitcher JA, Lefkowitz RJ. Targeting G proteincoupled receptor kinases to their receptor substrates. J Membr Biol 1997; 157: 1-8.
12. Goodman OB Jr, Krupnick JG, Santini F, et al. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 1996; 383: 447-50.
13. Krupnick JG, Goodman OB Jr, Keen JH, Benovic JL. Arrestin/ clathrin interaction. Localization of the clathrin binding domain of nonvisual arrestins to the carboxy terminus. J Biol Chem 1997; 272: 15011-6.
14. Laporte SA, Oakley RH, Holt JA, Barak LS, Caron MG. The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits. J Biol Chem 2000; 275: 23120-6.
15. Laporte SA, Oakley RH, Zhang J, Holt JA, Ferguson SS, Caron MG, Barak LS. The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci USA 1999; 96: 3712-7.
16. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 2000; 275: 17201-10.
17. Charest PG, Terrillon S, Bouvier M. Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep 2005; 6: 334-40.
18. Miller WE, Lefkowitz RJ. Expanding roles for beta-arrestins as scaffolds and adapters in GPCR signaling and trafficking. Curr Opin Cell Biol 2001; 13: 139-45.
19. Perry SJ, Lefkowitz RJ. Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol 2002; 12: 130-8.
20. Maudsley S, Martin B, Luttrell LM. The origins of diversity and specificity in G protein-coupled receptor signaling. J Pharmacol Exp Ther 2005; 314: 485-94.
21. Shenoy SK, Lefkowitz RJ. Seven-transmembrane receptor signaling through beta-arrestin. Sci STKE 2005: cm10.
22. Luttrell LM, Ferguson SS, Daaka Y, et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999; 283: 655-61.
23. Luttrell LM, Roudabush FL, Choy EW, et al. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA 2001; 98: 2449-54.
24. Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 2001; 294: 1307-13.
25. Perry SJ, Baillie GS, Kohout TA, et al. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 2002; 298: 834-6.
26. Nelson CD, Perry SJ, Regier DS, Prescott SM, Topham MK, Lefkowitz RJ. Targeting of diacylglycerol degradation to M1 muscarinic receptors by beta-arrestins. Science 2007; 315: 663-6.
27. Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ. beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc Natl Acad Sci USA 2004; 101: 8603-7.
28. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122: 261-73.
29. Luttrell LM, Gesty-Palmer D. Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 2010; 62: 305-30.
30. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 2010; 9: 373-86.
31. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. Annu Rev Physiol 2007; 69: 483-510.
32. Holloway AC, Qian H, Pipolo L, et al. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol 2002; 61: 768-77.
33. Ahn S, Nelson CD, Garrison TR, Miller WE, Lefkowitz RJ. Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc Natl Acad Sci USA 2003; 100: 1740-4.
34. Wei H, Ahn S, Shenoy SK, et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 2003; 100: 10782-7.
35. Baker JG, Hall IP, Hill SJ. Agonist and inverse agonist actions of-blockers at the human--2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 2003; 64: 1357-69.
36. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, Pineyro G. PP-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G proteincoupled receptors. Proc Natl Acad Sci USA 2003; 100: 11406-11.
37. Galandrin S, Oligny-Longpré G, Bonin H, Ogawa K, Galés C, Bouvier M. Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the tt1-adrenergic receptor. Mol Pharmacol 2008; 74: 162-172.
38. Wisler JW, DeWire SM, Whalen EJ, et al. A unique mechanism of β-blocker action: carvedilol stimulates---arrestin signaling. Proc Natl Acad Sci USA 2007; 104: 16657-62.
39. Zidar DA, Violin JD, Whalen EJ, Lefkowitz RJ. Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci USA 2009; 106: 9649-54.
40. Rengo G, Lymperopoulos A, Koch WJ. Future g protein-coupled receptor targets for treatment of heart failure. Curr Treatment Options Cardiovasc Med 2009; 11: 328-38.
41. Rengo G, Lymperopoulos A, Zincarelli C, et al. Myocardial adenoassociated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009; 119: 89-98.
42. Xiang Y, Kobilka BK. Myocyte adrenoceptor signaling pathways. Science 2003; 300: 1530-2.
43. Communal, C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)-and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 1999; 100: 2210-2.
44. Bristow MR. α-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-69.
45. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55.
46. Noma T, Lemaire A, Naga Prasad SV, et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 2007; 117: 2445-58.
47. Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, Lefkowitz RJ. LL-arrestin-biased agonism at the--2-adrenergic receptor. J Biol Chem 2008; 283: 5669-5676.
48. Woo AY, Wang TB, Zeng X, et al. Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes. Mol Pharmacol 2009; 75: 158-65.
49. Zhai P, Yamamoto M, Galeotti J, et al. Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 2005; 115: 3045-56.
50. Aplin M, Christensen GL, Schneider M, et al. Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes. Basic Clin Pharmacol Toxicol 2007; 100: 296-301.
51. Rajagopal K, Whalen EJ, Violin JD, et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA 2006; 103: 16284-9.
52. Kukkonen JP. Regulation of receptor-coupling to (multiple) G proteins. A challenge for basic research and drug discovery. Receptors and Channels 2004; 10: 167-83.
53. Wang Q, Zhao J, Brady AE, Feng J, et al. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science 2004; 304: 1940-1944.
54. Schmid CL, Bohn LM. Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther 2009; 121: 285-93.
55. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689-97.
56. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol 2005; 186: 1-20.
57. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007; 113: 267-78.
58. Ganguly A, Davis JS. Role of calcium and other mediators in aldosterone secretion from the adrenal glomerulosa cells. Pharmacol Rev 1994; 46: 417-47.
59. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
60. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Soltys S, Koch WJ. An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc Natl Acad Sci USA 2009; 106: 5825-30.
61. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Koch WJ. Adrenal Beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. J Am Coll Cardiol 2011; 57: 356-65.
62. Lymperopoulos A, Rengo G, Magafa V, Cordopatis P, Koch WJ. Biased Agonism/Antagonism of BB-Arrestin activation by the Angiotensin II Type 1 Receptor: A Study of Sartans and Angiotensin II Analogs Using Aldosterone Turnover as a Readout. J. Card. Fail. Suppl. 1 2010; 16: S30-1.
63. Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med 2007; 13: 315-23.
64. Lymperopoulos A, Rengo G, Koch WJ. Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Tr Mol Med 2007; 13: 503-11.
65. Kim J, Zhang L, Peppel K, et al. Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ Res 2008; 103: 70-9.
66. Kim J, Ahn S, Rajagopal K, Lefkowitz RJ. Independent betaarrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J Biol Chem 2009; 284: 11953-62.
67. Ahn S, Kim J, Hara MR, Ren XR, Lefkowitz RJ. Beta-arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. J Biol Chem 2009; 284: 8855-65.
68. Kather H, Aktories K, Schulz G, Jakobs KH. Islet-activating protein discriminates the antilipolytic mechanism of insulin from that of other antilipolytic compounds. FEBS Lett 1983; 161: 149-52.
69. Pike NB. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest 2005; 115: 3400-3.
70. Walters RW, Shukla AK, et al. Beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest 2009; 119: 1312-21.
71. Richman JG, Kanemitsu-Parks M, Gaidarov I, et al. Nicotinic acid receptor agonists differentially activate downstream effectors. J Biol Chem 2007; 282: 18028-36.
72. Semple G, Skinner PJ, Gharbaoui T, et al. 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J Med Chem 2008; 51: 5101-8.